Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Center for Cell Engineering and Antibody is the primary antibody research and development arm of the Shanghai Institute of Biological Products (SIBP), which is a subsidiary of China National Biotec Group (CNBG) under Sinopharm. The center focuses on the development of therapeutic monoclonal antibodies, particularly biosimilars and biobetters for oncology and autoimmune diseases. In 2023, its Trastuzumab biosimilar (SIBP-01) received marketing authorization from the NMPA in China. The center maintains a robust pipeline of biosimilars for major oncology targets like CD20 and EGFR, and autoimmune targets like TNF.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Center for Cell Engineering and Antibody.